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At a Glance Commentary 
Scientific Knowledge on the Subject: 
 Patients with COPD frequently experience cardiovascular disease (CVD). 
 COPD exacerbations are associated with increased systemic inflammation, which is a 
risk factor for CVD. 
 Preliminary data suggest that acute exacerbations of COPD (AECOPD) are associated 
with an increased risk of subsequent CVD events, but studies have relied on 
administrative data or non-adjudicated CVD event data. 
 
What This Study Adds to the Field 
 In this large cohort of 16,485 COPD patients with CVD or multiple CVD risk factors, 
exacerbations were followed by an increased risk of adjudicated CVD events, especially 
in hospitalized COPD patients and in the first 30 days following AECOPD. 
 1 
Abstract 1 
Rationale: Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are 2 
common, associated with acute inflammation, and may increase subsequent cardiovascular 3 
disease (CVD) risk. 4 
Objective: Determine if AECOPD events are associated with increased risk of subsequent 5 
CVD. 6 
Methods: A secondary cohort analysis of the Study to Understand Mortality and MorbidITy 7 
(SUMMIT) trial, a convenience sample of current/former smokers with moderate COPD from 8 
1,368 centers in 43 countries. All had CVD or increased CVD risk. AECOPD was defined as an 9 
increase in respiratory symptoms requiring treatment with antibiotics, systemic corticosteroids 10 
and/or hospitalization. CVD events were a composite outcome of cardiovascular death, 11 
myocardial infarction, stroke, unstable angina, and transient ischemic attack. All CVD events 12 
were adjudicated. Cox proportional hazards models compared the hazard for a CVD event 13 
prior to AECOPD versus following AECOPD. 14 
Measurements and Main Results:  15 
Among 16,485 participants in SUMMIT, 4,704 participants had at least one AECOPD and 688 16 
had at least one CVD event. The hazard ratio (HR) for CVD events following AECOPD was 17 
increased, particularly in the first 30 days following AECOPD (HR 3.8; 95%CI: 2.7 to 5.5) and 18 
was elevated up to one year post-AECOPD. The 30-day HR following hospitalized AECOPD 19 
was more than two-fold greater (HR 9.9; 95%CI: 6.6 to 14.9). 20 
 2 
Conclusions: In COPD patients with CVD or risk factors for CVD, exacerbations confer an 21 
increased risk of subsequent CVD events, especially in hospitalized patients and within the 22 
first 30 days post-exacerbation. Patients and clinicians should have heightened vigilance for 23 
early CVD events following AECOPD.  24 
Trial Registration: ClinicalTrials.gov NCT01313676 25 
Funding sources: GlaxoSmithKline provided funding for the original SUMMIT trial 26 
(NCT01313676, GSK113782). GlaxoSmithKline employees performed the statistical analysis 27 
and participated in the writing group team, but GlaxoSmithKline did not direct or make final 28 
decisions regarding study conception, analysis of results, manuscript writing, or the decision to 29 
submit for publication. 30 
  31 
 3 
 32 
INTRODUCTION 33 
Ischemic heart disease, stroke, and chronic obstructive pulmonary disease (COPD) are three 34 
leading causes of death globally.1 These diseases share common risk factors such as older 35 
age and cigarette smoking, yet data suggest that COPD and lower lung function are 36 
independent risk factors for cardiovascular disease (CVD), even after adjustment for traditional 37 
CVD risk factors.2-4  38 
The mechanisms by which COPD increases CVD risk are not clear, but patients with COPD 39 
often display abnormally high concentrations of circulating systemic inflammatory biomarkers 40 
such as C-reactive protein, interleukin-6, and fibrinogen5—biomarkers that predict CVD risk in 41 
the general population6,7 and in COPD.8 Acute exacerbations of COPD (AECOPD) are often 42 
associated with particularly high concentrations of these biomarkers9 which can be slow to 43 
return to baseline.10  44 
Additionally, many AECOPD events are triggered by infections,11 and data have shown that 45 
infections (mostly respiratory, but also urinary and gastrointestinal) are associated with an 46 
increased risk for subsequent CVD events.12-16 The reasons for this are not clear, but 47 
hypotheses have focused on infections as inducers of systemic inflammation and pro-48 
coagulant pathways that subsequently lead to cardiovascular events. 49 
Two previous studies have suggested that AECOPD increases risk for subsequent CVD, but 50 
both had significant methodologic limitations including use of administrative data to define 51 
COPD, AECOPD and CVD events17 or use of non-adjudicated adverse event reporting data.18 52 
 4 
The Study to Understand Mortality and MorbidITy (SUMMIT) trial was an international, 53 
multicenter trial of patients with COPD and either a history of CVD or heightened risk for CVD. 54 
SUMMIT assessed the impact of inhaler treatments on mortality and rigorously adjudicated 55 
CVD events, therefore reducing the risk of ascertainment bias and providing more accurate 56 
estimates of risk. We hypothesized that time periods following AECOPD would be associated 57 
with higher risk for CVD events compared with time periods free of AECOPD.   58 
Some of the results of this study have been previously reported in the form of an abstract.19 59 
METHODS 60 
A detailed description of our methods is included with the Online Supplement. In brief, we 61 
performed a post-hoc cohort analysis using data in SUMMIT, a double-blind, parallel group, 62 
placebo-controlled, randomized trial conducted at 1,368 centers in 43 countries between 2011 63 
and 2015. Details of the study design and main results are published.20,21 Participants 64 
(n=16,485) were randomly assigned to receive either inhaled placebo, fluticasone furoate, 65 
vilanterol, or the combination of fluticasone furoate and vilanterol. The study showed no 66 
significant differences in risk of death or cardiovascular events between the four arms of the 67 
trial.  68 
Participants were current or former smokers with at least a 10-pack-year smoking history, aged 69 
40–80 years with a ratio of forced expiratory volume in 1 s to forced vital capacity (FEV1/FVC) 70 
≤70%, FEV1 50%-70% of predicted, and a modified Medical Research Council dyspnea scale 71 
score of ≥2. Participants 40-59 years old were required to have a history of CVD, defined as 72 
coronary artery disease, peripheral arterial disease, stroke, myocardial infarction, or diabetes 73 
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mellitus with target organ disease. Participants 60-80 years old could have either a history of 74 
CVD or increased risk for CVD, defined as receiving medication for two or more of the 75 
following: hypercholesterolemia, hypertension, diabetes mellitus, or peripheral arterial disease.  76 
Exclusion criteria included respiratory disorders other than COPD, lung reduction surgery, 77 
receiving long-term oxygen, chronic oral corticosteroid therapy, severe heart failure (New York 78 
Heart Association Class IV or ejection fraction <30%), life expectancy less than three years, 79 
and end-stage chronic renal disease.  80 
Participants were seen every three months at which time data relating to AECOPD and CVD 81 
were assessed.   82 
Statistical analysis 83 
We used Cox proportional hazards models with time-dependent ‘period’ covariates, where the 84 
hazard for a CVD event was compared between the period prior to AECOPD (‘baseline’ in our 85 
tables) and following AECOPD (Online Supplement Figure S1). AECOPD was defined as an 86 
increase in respiratory symptoms requiring treatment with antibiotics, systemic corticosteroids 87 
and/or hospitalization. Our primary outcome was a composite CVD outcome that included 88 
cardiovascular death, myocardial infarction, stroke, unstable angina, and transient ischemic 89 
attack. A clinical endpoint committee (CEC) used data from medical records, witness 90 
interviews, autopsy reports, and death certificates to adjudicated all CVD events using 91 
standardized guidelines.22,23 medical records, witness interviews, autopsy reports, and death 92 
certificates. 93 
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We excluded events where AECOPD and CVD were reported on the same day, as we were 94 
unable to determine which event happened first. We analyzed the hazard of post-AECOPD 95 
CVD events at 1-30 days, 31-90 days, 91 days-1 year, and >1 year following AECOPD events. 96 
Covariates are detailed in our table legends. In cases where participants experienced more 97 
than one AECOPD, only the first was used. Data were censored after the first CVD event. 98 
Secondary analyses focused on: 1) only hospitalized AECOPDs, 2) only myocardial 99 
infarctions, 3) comparison of those with established CVD versus those with only increased 100 
CVD risk, 4) restriction to each of the four arms of the trial, and 5) restriction to only those who 101 
experienced an AECOPD event during the study.  102 
 103 
RESULTS 104 
Among the 16,485 participants in SUMMIT, 75% were male, 47% were current smokers, mean 105 
body mass index (BMI) was 28 kg/m2 and 39% had a history of one or more AECOPD events 106 
in the year prior to enrolment (Table 1). 107 
Median participant on-treatment follow up time was 1.5 years with a total of 26,946 patient 108 
years of follow-up. During follow-up, 4,704 participants had at least one AECOPD and 688 had 109 
at least one adjudicated CVD event. The first CVD event was CV death in 271, myocardial 110 
infarction in 173, stroke in 127, unstable angina in 83, and transient ischemic attack in 34. 111 
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Depending on the particular analysis, between 0 to 9 participants were excluded due to 112 
reporting CVD and AECOPD on the same day.  113 
A total of 487 participants experienced a CVD event during the baseline period (487 events in 114 
21,624 patient years is 2.3 per 100 patient-years). Between days 1 to 30 following AECOPD, 115 
32 participants experienced a CVD event (8.8 per 100 patient-years); 29 participants had a 116 
CVD event between days 31 to 90 (4.4 per 100 patient-years); 91 participants had a CVD 117 
event between day 91 to 1 year (4.0 per 100 patient-years) and 41 participants had a CVD 118 
event after 1 year (2.4 per 100 patient-years). Compared with pre-AECOPD baseline periods, 119 
the hazard of CVD events following AECOPD was increased, particularly in the first 30 days 120 
following AECOPD (HR 3.8; 95%CI: 2.7 to 5.5), though it remained increased between 31 121 
days - 90 days and 91 days - 1 year, and was no longer increased beyond 1 year following 122 
AECOPD (Table 2 and Figure 1 2). 123 
In a further analysis, we restricted the AECOPD events to only hospitalized AECOPD events 124 
and considered participants who had a non-hospitalized AECOPD to remain in the baseline 125 
period. A total of 605 participants experienced a CVD event during the baseline period (2.4 per 126 
100 patient-years). Between days 1 to 30 following hospitalized AECOPD, 24 participants 127 
experienced a CVD event (26.7 per 100 patient-years); 15 participants had a CVD event 128 
between days 31 to 90 (9.9 per 100 patient-years); 24 participants had a CVD event between 129 
day 91 to 1 year (4.9 per 100 patient-years) and 11 participants had a CVD event after 1 year 130 
(3.3 per 100 patient-years).  In this case, the post-AECOPD hazard for CVD events was again 131 
particularly increased in the first 30 days following hospitalized AECOPD (HR 9.9; 95%CI: 6.6 132 
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to 14.9), remained increased between 31 days - 90 days and 91 days - 1 year, but was not 133 
increased beyond one year following hospitalized AECOPD (Table 2 and Figure 1 2). 134 
Analyses restricted only to those who experienced an AECOPD event during the study 135 
(n=4,629 with all covariates) showed that the hazard for CVD following AECOPD was again 136 
particularly increased in the first 30 days following AECOPD (HR 6.4; 95% CI: 4.1 to 10.2). The 137 
hazard was attenuated, but still significant, between 31 days - 1 year following AECOPD, and 138 
remained slightly elevated >1 year after AECOPD (Table 3). 139 
Analyses restricted to only myocardial infarction events (i.e., excluding other non-myocardial 140 
infarction CVD events) showed similar results, with a substantially increased risk of myocardial 141 
infarction in the first 30 days following AECOPD, a lower, but still significant, risk between 31 142 
days - 1 year, and no significant increased risk beyond 1 year (Online Supplement, Table 143 
S1).  144 
Analyses stratified by whether participants entered the study with a history of established CVD 145 
or CVD risk are shown in Online Supplement, Table S2. The hazard ratio for experiencing a 146 
CVD event following AECOPD was again most pronounced in the first 30 days following 147 
AECOPD, regardless of whether participants entered the study with established CVD or CVD 148 
risk. Among those with established CVD, the younger and older age groups had similar 95% 149 
CI bounds for the hazard ratios at each time period post-AECOPD, but there were very few 150 
CVD events, so these estimates may not be reliable.  151 
 9 
Lastly, we analyzed the hazard for CVD following AECOPD separately in each of the four 152 
original trial arms of the parent SUMMIT study. Results were again similar to that observed in 153 
our other analyses, with each arm demonstrating hazard ratios that were particularly increased 154 
in the first 30 days following AECOPD, remained increased between 31 days - 1 year, and 155 
were no longer significant beyond 1 year following AECOPD (Online Supplement, Table S3). 156 
 157 
DISCUSSION 158 
This analysis of prospectively collected data from a multi-center, international study of patients 159 
with moderately severe COPD and rigorously adjudicated CVD events supports the notion that 160 
AECOPD increases the risk for subsequent CVD events, especially in the first 30 days 161 
following an AECOPD. Moreover, the observed effect size was substantial, with a 4-fold 162 
increased hazard for CVD events following AECOPD, and a 10-fold increase in those 163 
hospitalized with AECOPD. These results suggest that clinicians and patients need to be 164 
vigilant for the occurrence of CVD events following AECOPD, especially in those hospitalized 165 
with AECOPD. 166 
Our findings are notable for remarkable consistency among the primary analysis and the 167 
multiple secondary analyses regarding the particularly high CVD risk in the first 30 days 168 
following AECOPD, whether we analyzed all AECOPD events, hospitalized AECOPD events, 169 
myocardial infarctions only, or stratified by age and established CVD versus CVD risk. Our 170 
sample of over 16,000 study participants is one of the largest prospective COPD studies 171 
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conducted to date and the multi-center, multi-national design enrolled from multiples sites 172 
and countries increases the generalizability to patients seen in varying clinical settings. Our 173 
findings are further strengthened by the blinded adjudication of CVD events. This adjudication 174 
provides us with a high degree of confidence regarding the validity of the CVD events. 175 
Our findings validate preliminary observations in the Understanding Potential Long-term 176 
Impacts on Function with Tiotropium (UPLIFT) trial, where AECOPD was associated with a 177 
higher risk of cardiovascular SAEs in both the first 30 and first 180 days post-AECOPD, with 178 
higher risk in the first 30 days.18 CVD event data in UPLIFT consisted of only serious adverse 179 
event (SAE) reporting data without detailed adjudication, and the analysis did not include 180 
adjustment for multiple potential confounders. Unlike SUMMIT, UPLIFT did not specifically 181 
select for COPD patients at risk for CVD, but in both UPLIFT and our SUMMIT results, 182 
associations between AECOPD and CVD were present whether patients entered the studies 183 
with a history of previously diagnosed CVD or not.  184 
Our findings also build upon a previous study of AECOPD and CVD relationships using 185 
administrative data in England and Wales. Among those with administrative codes for 186 
physician-diagnosed COPD (not necessarily confirmed by spirometry), prescriptions for oral 187 
antibiotics and corticosteroids (considered a surrogate marker of AECOPD) were associated 188 
with a higher risk for subsequent myocardial infarctions and stroke.17 These associations were 189 
dependent on the outcomes and time-period examined. For example, the increased risk for 190 
myocardial infarction was only observed for five days following a prescription for both 191 
antibiotics and steroids—there was no association with antibiotics alone, steroids alone, or 192 
beyond five days of the combination prescription. However, for stroke, the association was 193 
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significant up to 49 days after a prescription for a steroid or an antibiotic, but not the 194 
combination steroid plus antibiotic. These complex observations may reflect the limitations of 195 
administrative data, as compared with our study’s strict criteria for spirometry confirmation of 196 
COPD, prospective collection of pre-defined AECOPD and CVD data, and detailed 197 
adjudication of CVD events. 198 
AECOPD events are associated with elevated concentrations of circulating pro-inflammatory 199 
biomarkers24 that can be slow to return to baseline.10  The high initial concentrations with slow 200 
recovery might help explain why we observed the most risk for CVD in the first 30 days post-201 
AECOPD, but we continued to observe a statistically significant, albeit much smaller, risk up to 202 
one year post-AECOPD. The prolonged duration of increased CVD risk is consistent with 203 
studies that have shown that respiratory events such as pneumonia13 and other respiratory 204 
infections14 are associated with prolonged CVD risk.  205 
Inflammation might also explain why hospitalized AECOPD patients had a 30-day CVD risk 206 
more than double that seen in those with less severe AECOPD. Hospitalized AECOPD 207 
episodes are often associated with higher concentrations of circulating pro-inflammatory 208 
biomarkers compared to AECOPD events treated outside of the hospital.25 We did not 209 
measure biomarkers in this study, so we were unable to determine the contribution of 210 
inflammation to post-AECOPD CVD risk. We were also unable to test other potential 211 
mechanisms such as AECOPD leading to hypoxemia, increased respiratory muscle work 212 
diverting perfusion from the coronary circulation, induction of a pro-thrombotic state, increases 213 
in blood pressure, or worsening adherence to non-respiratory medications. 214 
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From a therapeutic standpoint, our data suggest that the immediate post-AECOPD period is a 215 
window of heightened CVD susceptibility, and therefore future studies should test interventions 216 
in this period to reduce CVD risk. Possible interventions to test might include established CVD 217 
therapies (e.g. antiplatelet agents, statins, and/or beta blockers) and/or experimental CVD 218 
interventions (e.g. anti-inflammatory drugs). 219 
Our study has several important limitations. SUMMIT participants were selected based on 220 
being at high CVD risk either due to pre-existing disease or having multiple risk factors for 221 
CVD. Although estimates of CVD prevalence in patients with COPD have ranged from 28% to 222 
70%,3 our findings may not apply to COPD patients without CVD or CVD risk factors. SUMMIT 223 
participation was also restricted to those with FEV1 between 50%-70% of predicted, so we 224 
cannot generalize our findings to those with milder or more severe airflow limitation. Our 225 
follow-up time was also relatively short, at a median of 1.5 years. While data from our study 226 
and other studies suggest that most of the excess CVD risk occurs within the first year after 227 
AECOPD, we had limited power to study long-term event risk beyond one year. Lastly, 228 
although CVD events were adjudicated, AECOPD events were self-reported and not 229 
adjudicated. Therefore, we cannot exclude the possibility that some AECOPD events 230 
were CVD events to begin with. However, our AECOPD definition is that used by nearly 231 
every contemporary COPD trial and is a definition that has proven to be modifiable by 232 
treatments such as inhalers and oral medications.26 Moreover, we found even stronger 233 
associations in hospitalized patients who have presumably had typically undergo more 234 
detailed assessments for other clinical etiologies of acute-onset dyspnea (e.g. pneumonia, 235 
myocardial infarction, pulmonary embolism) compared to outpatients. Therefore, we think 236 
misclassification of AECOPD is not likely. 237 
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 238 
CONCLUSION 239 
In COPD patients with CVD or risk factors for CVD, exacerbations confer an increased risk of 240 
subsequent CVD events, especially in hospitalized patients and within the first 30 days post-241 
exacerbation. Patients and clinicians should have heightened vigilance for early CVD events in 242 
this patient group following AECOPD. 243 
  244 
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Figure 1. Graphical representation of analytic method. All study participants with any follow-up 
time contribute to the analysis.  Participants can have one of four possible patterns, as 
graphically shown below, from the top down: 1) No acute exacerbation of chronic obstructive 
pulmonary disease [AECOPD] (black bars) and no cardiovascular disease [CVD] events (as 
depicted by red bolts), 2) No AECOPD, but with CVD event, 3) AECOPD (as indicated by blue 
arrow/bar), but with no CVD event, and 4) AECOPD and CVD event.  All participants with any 
follow-up time contribute to baseline hazard data for CVD events. Participants with AECOPD 
events contribute baseline hazard data for both baseline, exacerbation-free periods (black 
bars) and comparison data regarding post-AECOPD hazard data at 1-30 days after AECOPD 
(green bars), 31-90 days after AECOPD (yellow bars), 91 days-1 year after AECOPD (orange 
bars) and >1 year after AECOPD (grey bars). Data are censored at the time of a CVD event. 
Secondary analyses included: 1) only hospitalized AECOPD events, where participants who 
had a non-hospitalized AECOPD remained in the baseline period (Table 2), and 2) restriction 
to only the last two groups who experienced an AECOPD during the study (Table 3). 
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Figure 1 2. Hazard ratios (95% confidence intervals) for cardiovascular disease 
(cardiovascular death, myocardial infarction, stroke, unstable angina, and transient ischemic 
attack) following an acute exacerbation of chronic obstructive pulmonary disease.  
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Table 1. Study participant characteristics. Reported as mean (SD) or n (%). 
 Total (n = 16,485) 
Age (years) 65 (8) 
Female 4,196 (25%) 
Race  
      White  13,357 (81%) 
      Asian 2,724 (17%) 
      Other  404 (2%) 
Body mass index (kg/m2) 28 (6) 
Current Smokers 7,678 (47%) 
Smoking History (pack-years) 41 (24) 
Systolic blood pressure, mmHg 135 (15) 
Diastolic blood pressure, mmHg 80 (10) 
Cardiac comorbidities  
      Coronary artery disease 8,379 (51%) 
      Previous myocardial infarction 2,774 (17%) 
      Previous stroke 1,595 (10%) 
      Hypercholesterolemia 11,518 (70%) 
      Hypertension 14,851 (90%) 
      Diabetes mellitus 4,997 (30%) 
Cardiac medications  
      Antiplatelet 8,517 (52%) 
      Statin 10,721 (65%) 
      Beta-blocker 5,667 (34%) 
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      Diuretic 6,148 (37%) 
Post-Bronchodilator FEV₁ (L)      1.70 (0.40) 
% Predicted post-bronchodilator FEV₁ 59.7 (6.1) 
Pre-study COPD inhaler therapy  
      Long-acting β-agonist 5,769 (35%) 
      Long-acting muscarinic antagonist 2,550 (15%) 
      Inhaled corticosteroid 5,486 (33%) 
Pre-study exacerbations in 12 months before study  
      0 10,021 (61%) 
      1 4,020 (24%) 
     2+ 2,444 (15%) 
 
Abbreviations: COPD=chronic obstructive pulmonary disease; FEV1=forced expiratory volume in 1 second.  
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Table 2. Hazard ratios for cardiovascular disease (CVD) event (cardiovascular death, 
myocardial infarction, stroke, unstable angina, and transient ischemic attack) following an 
acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Analysis shown for 
all exacerbations (top) and for exacerbations requiring hospitalization (bottom). 
Period 
Number of 
Participants 
in Period 
Observed 
Follow-up in 
Period 
(Patient-
Years) 
Number of 
Participants 
with 
adjudicated 
CVD event 
Hazard Ratio (95% CI) 
All Exacerbations 
Baseline, 
AECOPD-free 
16,477 21,624 487 -reference- 
1 – 30 days 4,639 363 32 3.8 (2.7 to 5.5) 
31 days – 90 days 4,235 658 29 1.9 (1.3 to 2.7) 
91 days – 1 year 3,779 2,267 91 1.9 (1.5 to 2.4) 
>1 year 2,179 1,744 41 1.2 (0.8 to 1.7) 
Exacerbations Requiring Hospitalization 
Baseline, 
AECOPD-free 
16,476 25,595 605 -reference- 
1 – 30 days 1,243 90 24 9.9 (6.6 to 14.9) 
31 – 90 days 998 152 15 3.7 (2.2 to 6.1) 
91 days – 1 year 862 487 24 2.0 (1.3 to 3.0) 
>1 year 447 330 11 1.3 (0.7 to 2.6) 
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Covariates included: AECOPD period (baseline free of AECOPD or other post-AECOPD 
periods as in Figure 1), treatment assignment arm, age, sex, body mass index (BMI), region, 
race, ethnicity, ischemic and vascular indicators (e.g. previous treatment of coronary or 
vascular disease), cardiovascular disease/risk indicators (with CVD; with CV risk), smoking 
status, previous exacerbation history, and percent predicted post-bronchodilator FEV1 
8 participants were excluded from the ‘All Exacerbations’ analysis due to experiencing an 
AECOPD and CVD event on the same day; 9 were excluded from the ‘Exacerbations 
Requiring Hospitalization’ analysis due to experiencing an AECOPD and CVD event on the 
same day. 183 participants were excluded from the calculation of the Hazard Ratios in both 
analyses because they did not have all model covariates.   
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Table 3. Secondary analysis restricted to only those study participants who experienced an 
AECOPD event during the study. Hazard ratios for CVD events following an AECOPD. Due to 
small numbers in this restricted analysis, the post-AECOPD periods of 31-90 days and 90 
days-1 year were combined. 
Period 
Number of 
Participants 
in Period 
Observed 
Follow-up in 
Period 
(Patient-
Years) 
Number of 
Participants 
with 
adjudicated 
CVD event 
Hazard Ratio (95% CI) 
Baseline, 
AECOPD-free 
4,696 3,695 55 -reference- 
1 – 30 days 4,639 363 32 6.4 (4.1 to 10.2) 
31 days – 1 year 4,235 2,926 120 3.0 (2.1 to 4.4) 
>1 year 2,179 1,744 41 1.8 (1.1 to 3.1) 
Covariates included: AECOPD period (baseline free of AECOPD or other post-AECOPD 
periods as in Figure 1), treatment assignment arm, age, sex, body mass index (BMI), region, 
race, ethnicity, ischemic and vascular indicators (e.g. previous treatment of coronary or 
vascular disease), cardiovascular disease/risk indicators (with CVD; with CV risk), smoking 
status, previous exacerbation history, and percent predicted post-bronchodilator FEV1 
8 participants were excluded due to experiencing an AECOPD and CVD event on the same 
day. 67 participants were excluded from the calculation of the Hazard Ratios because they did 
not have all model covariates. 
 
